NEW YORK (GenomeWeb News) — A group of European research institutes has hired Biobase to help it develop informatics tools and experimental methods for identifying therapeutic targets, the company said today.
Biobase said it will help develop bioinformatics and cheminformatics for the European Union-commissioned Net2Drug project, which is a consortium of institutes from Europe and Russia that represents interdisciplinary fields including toxicology, systems biology, pharmacology, and cancer.
The project “will integrate different omics datasets such as proteomics and genomics into cohesive networks” to help study diseases.
Any resulting methods or technologies will be tested on “certain tumor types,” particularly on breast cancer, said Alexander Kel, Biobase senior vice president of R&D.
Net2Drug is part of the EU’s Sixth Framework program, which was funded with $2.5 billion between 2002 and 2006, and which sets aside as much as $475 million for cancer research.
Financial terms of the agreement were not released.